Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1998 1
2000 1
2001 1
2002 2
2005 1
2007 2
2008 4
2009 2
2011 1
2012 1
2014 1
2015 3
2016 5
2017 5
2018 10
2019 7
2020 8
2021 13
2022 14
2023 9
2024 2

Text availability

Article attribute

Article type

Publication date

Search Results

86 results

Results by year

Filters applied: . Clear all
Page 1
Luspatercept in Patients with Lower-Risk Myelodysplastic Syndromes.
Fenaux P, Platzbecker U, Mufti GJ, Garcia-Manero G, Buckstein R, Santini V, Díez-Campelo M, Finelli C, Cazzola M, Ilhan O, Sekeres MA, Falantes JF, Arrizabalaga B, Salvi F, Giai V, Vyas P, Bowen D, Selleslag D, DeZern AE, Jurcic JG, Germing U, Götze KS, Quesnel B, Beyne-Rauzy O, Cluzeau T, Voso MT, Mazure D, Vellenga E, Greenberg PL, Hellström-Lindberg E, Zeidan AM, Adès L, Verma A, Savona MR, Laadem A, Benzohra A, Zhang J, Rampersad A, Dunshee DR, Linde PG, Sherman ML, Komrokji RS, List AF. Fenaux P, et al. Among authors: gotze ks. N Engl J Med. 2020 Jan 9;382(2):140-151. doi: 10.1056/NEJMoa1908892. N Engl J Med. 2020. PMID: 31914241 Free article. Clinical Trial.
Sorafenib Maintenance After Allogeneic Hematopoietic Stem Cell Transplantation for Acute Myeloid Leukemia With FLT3-Internal Tandem Duplication Mutation (SORMAIN).
Burchert A, Bug G, Fritz LV, Finke J, Stelljes M, Röllig C, Wollmer E, Wäsch R, Bornhäuser M, Berg T, Lang F, Ehninger G, Serve H, Zeiser R, Wagner EM, Kröger N, Wolschke C, Schleuning M, Götze KS, Schmid C, Crysandt M, Eßeling E, Wolf D, Wang Y, Böhm A, Thiede C, Haferlach T, Michel C, Bethge W, Wündisch T, Brandts C, Harnisch S, Wittenberg M, Hoeffkes HG, Rospleszcz S, Burchardt A, Neubauer A, Brugger M, Strauch K, Schade-Brittinger C, Metzelder SK. Burchert A, et al. Among authors: gotze ks. J Clin Oncol. 2020 Sep 10;38(26):2993-3002. doi: 10.1200/JCO.19.03345. Epub 2020 Jul 16. J Clin Oncol. 2020. PMID: 32673171 Clinical Trial.
Long-Term Efficacy and Safety of Luspatercept for Anemia Treatment in Patients With Lower-Risk Myelodysplastic Syndromes: The Phase II PACE-MDS Study.
Platzbecker U, Götze KS, Kiewe P, Germing U, Mayer K, Radsak M, Wolff T, Chromik J, Sockel K, Oelschlägel U, Haase D, Illmer T, Al-Ali HK, Silling G, Reynolds JG, Zhang X, Attie KM, Shetty JK, Giagounidis A. Platzbecker U, et al. Among authors: gotze ks. J Clin Oncol. 2022 Nov 20;40(33):3800-3807. doi: 10.1200/JCO.21.02476. Epub 2022 Aug 23. J Clin Oncol. 2022. PMID: 35998303 Free PMC article. Clinical Trial.
Targeting FLT3 with a new-generation antibody-drug conjugate in combination with kinase inhibitors for treatment of AML.
Roas M, Vick B, Kasper MA, Able M, Polzer H, Gerlach M, Kremmer E, Hecker JS, Schmitt S, Stengl A, Waller V, Hohmann N, Festini M, Ludwig A, Rohrbacher L, Herold T, Subklewe M, Götze KS, Hackenberger CPR, Schumacher D, Helma-Smets J, Jeremias I, Leonhardt H, Spiekermann K. Roas M, et al. Among authors: gotze ks. Blood. 2023 Mar 2;141(9):1023-1035. doi: 10.1182/blood.2021015246. Blood. 2023. PMID: 35981498 Free article.
Luspatercept for the treatment of anaemia in patients with lower-risk myelodysplastic syndromes (PACE-MDS): a multicentre, open-label phase 2 dose-finding study with long-term extension study.
Platzbecker U, Germing U, Götze KS, Kiewe P, Mayer K, Chromik J, Radsak M, Wolff T, Zhang X, Laadem A, Sherman ML, Attie KM, Giagounidis A. Platzbecker U, et al. Among authors: gotze ks. Lancet Oncol. 2017 Oct;18(10):1338-1347. doi: 10.1016/S1470-2045(17)30615-0. Epub 2017 Sep 1. Lancet Oncol. 2017. PMID: 28870615 Clinical Trial.
Compartment-specific mutational landscape of clonal hematopoiesis.
Hartmann L, Hecker JS, Rothenberg-Thurley M, Rivière J, Jentzsch M, Ksienzyk B, Buck MC, van der Garde M, Fischer L, Winter S, Rauner M, Tsourdi E, Weidner H, Sockel K, Schneider M, Kubasch AS, Nolde M, Hausmann D, Lützner J, Goralski S, Bassermann F, Spiekermann K, Hofbauer LC, Schwind S, Platzbecker U, Götze KS, Metzeler KH. Hartmann L, et al. Among authors: gotze ks. Leukemia. 2022 Nov;36(11):2647-2655. doi: 10.1038/s41375-022-01700-3. Epub 2022 Sep 21. Leukemia. 2022. PMID: 36131041 Free PMC article.
Progressive disruption of hematopoietic architecture from clonal hematopoiesis to MDS.
Buck MC, Bast L, Hecker JS, Rivière J, Rothenberg-Thurley M, Vogel L, Wang D, Andrä I, Theis FJ, Bassermann F, Metzeler KH, Oostendorp RAJ, Marr C, Götze KS. Buck MC, et al. Among authors: gotze ks. iScience. 2023 Jul 10;26(8):107328. doi: 10.1016/j.isci.2023.107328. eCollection 2023 Aug 18. iScience. 2023. PMID: 37520699 Free PMC article.
86 results